Internal Medicine

Humans are visual animals. As the old adage goes: “Seeing is believing.” So it is perhaps not surprising

In vitro profiling specialist Bionas GmbH

Despite the wealth of in silico designs and in vitro assays that scientists use to identify new therapeutic compounds, a new drug often fails because of side effects noted during in vivo screening.

Companies collaborate to provide data on transfection of ATCC cell lines using Roche’s FuGENE reagents either by Roche scientists or via information culled from peer-reviewed publications.

Although researchers are increasingly using aptamers as high-specificity molecular probes, they generally need purified targets to generate these modified nucleic acids.

Total spending by research scientists on synthetic DNA oligonucleotides (oligos) is over US$700 million annually

Companies are expanding a 2005 co-marketing agreement into a full-fledged collaboration to develop new workflow solutions for the discovery of diagnostic markers and drug targets by glycomics analysis.

Biotek reached end of a years-long project to bring all software development and support in-house.

To focus its business on cell imaging and handling technologies, Evotec Technologies GmbH sold the core of its single-molecule detection (SMD) technology and related IP.